Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.

Cancer immunology, immunotherapy : CII - 1 Jun 2021

Yi Ming, Li Anping, Zhou Linghui, Chu Qian, Luo Suxia, Wu Kongming

Abstract excerpt

BACKGROUND: Lung adenocarcinoma (LUAD) is a common pulmonary malignant disease with a poor prognosis. There were limited studies investigating the influences of the tumor immune microenvironment on LUAD patients' survival and response to immune checkpoint inhibitors (ICIs). METHODS: Based on TCGA-LUAD dataset, we constructed a prognostic immune signature and validated its predictive capability in the internal as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Lymphocytes, Tumor-Infiltrating

Share to Macrophages

Share to Prognosis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33386920
DOI: 10.1007/s00262-020-02817-z
PMCID: PMC8139885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.PMID 33386920Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinomaSemantic proximity Read ↗

An Immune Gene Signature for Prediction of Overall Survival and Response to Immune Checkpoint Inhibitors Therapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

Immune Score Closely Associated With Tumor Microenvironment as A Prognostic Factor in Lung AdenocarcinomaSemantic proximity Read ↗

Analysis of Clinical Implications and Immune Landscape in Prognostic Model based on Immune Cell Signatures for Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.Semantic proximity Read ↗

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors.Semantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.